Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim AnalysisGlobeNewsWire • 03/31/23
Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific SessionGlobeNewsWire • 03/04/23
Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv MecarbilGlobeNewsWire • 02/28/23
Is a Surprise Coming for Cytokinetics (CYTK) This Earnings Season?Zacks Investment Research • 02/28/23
Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific SessionGlobeNewsWire • 02/24/23
Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant ProgramGlobeNewsWire • 01/30/23
Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart DrugInvestors Business Daily • 12/14/22
Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv MecarbilGlobeNewsWire • 12/13/22
Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv MecarbilGlobeNewsWire • 12/09/22
Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MNDGlobeNewsWire • 12/08/22
Cytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MNDGlobeNewsWire • 12/01/22
Cytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022GlobeNewsWire • 11/07/22